keyword
MENU ▼
Read by QxMD icon Read
search

Oncotype Dx

keyword
https://www.readbyqxmd.com/read/29316513/the-biology-of-male-breast-cancer
#1
REVIEW
Ian S Fentiman
Important differences have begun to emerge concerning the molecular profile of female and male breast cancer which may prove to be of therapeutic value. This review examined all the available data on the genomics of MBC. Most male cancers are ER+ve but without a corresponding increase in PR positivity and only a weaker association with estrogen-controlled markers such as PS2, HSP27 and Cathepsin-D. HER2 +ve cancers are rare in males and the role of androgen receptor is controversial. Although the Luminal A phenotype was the most frequent in both MBC and FBC, no Luminal B or HER2 phenotypes were found in males and the basal phenotype was very rare...
January 6, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29305309/evaluation-of-prognosis-in-hormone-receptor-positive-her2-negative-and-lymph-node-negative-breast-cancer-with-low-oncotype-dx-recurrence-score
#2
Jane Meisel, Chao Zhang, Cameron Neely, Pia Mendoza, Shuo You, Tatiana Han, Yuan Liu, Aysegul A Sahin, Ruth O'Regan, Xiaoxian Li
INTRODUCTION: Hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor-positive, HER2-negative, lymph node-negative cancers with Oncotype DX score ranges of 1 to 10 (1-10 group) and 11 to < 18 (11-18 group). PATIENTS AND METHODS: A total of 107 cases in the 1-10 group and 225 cases in the 11-18 group were reviewed. All patients received surgery...
December 14, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29304138/the-use-of-automated-ki67-analysis-to-predict-oncotype-dx-risk-of-recurrence-categories-in-early-stage-breast-cancer
#3
Satbir Singh Thakur, Haocheng Li, Angela M Y Chan, Roxana Tudor, Gilbert Bigras, Don Morris, Emeka K Enwere, Hua Yang
Ki67 is a commonly used marker of cancer cell proliferation, and has significant prognostic value in breast cancer. In spite of its clinical importance, assessment of Ki67 remains a challenge, as current manual scoring methods have high inter- and intra-user variability. A major reason for this variability is selection bias, in that different observers will score different regions of the same tumor. Here, we developed an automated Ki67 scoring method that eliminates selection bias, by using whole-slide analysis to identify and score the tumor regions with the highest proliferative rates...
2018: PloS One
https://www.readbyqxmd.com/read/29273958/biomarkers-in-breast-cancer-a-consensus-statement-by-the-spanish-society-of-medical-oncology-and-the-spanish-society-of-pathology
#4
R Colomer, I Aranda-López, J Albanell, T García-Caballero, E Ciruelos, M Á López-García, J Cortés, F Rojo, M Martín, J Palacios-Calvo
This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy...
December 22, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29243740/will-oncotype-dx-dcis-testing-guide-therapy-a-single-institution-correlation-of-oncotype-dx-dcis-results-with-histopathologic-findings-and-clinical-management-decisions
#5
Chieh-Yu Lin, Kelly Mooney, Winward Choy, Soo-Ryum Yang, Keegan Barry-Holson, Kathleen Horst, Irene Wapnir, Kimberly Allison
Given the increased detection rates of ductal carcinoma in situ (DCIS) and the limited overall survival benefit from adjuvant breast irradiation after breast-conserving surgery, there is interest in identifying subsets of patients who have low rates of ipsilateral breast tumor recurrence such that they might safely forgo radiation. The Oncotype DCIS score is a reverse transcription-PCR (RT-PCR)-based assay that was validated to predict which DCIS cases are most likely to recur. Clinically, these results may be used to assist in selecting which patients with DCIS might safely forgo radiation therapy after breast-conserving surgery; however, little is currently published on how this test is being used in practice...
December 15, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29241890/value-of-information-analysis-of-multiparameter-tests-for-chemotherapy-in-early-breast-cancer-the-optima-prelim-trial
#6
RANDOMIZED CONTROLLED TRIAL
Peter S Hall, Alison Smith, Claire Hulme, Armando Vargas-Palacios, Andreas Makris, Luke Hughes-Davies, Janet A Dunn, John M S Bartlett, David A Cameron, Andrea Marshall, Amy Campbell, Iain R Macpherson, Dan Rea, Adele Francis, Helena Earl, Adrienne Morgan, Robert C Stein, Christopher McCabe
BACKGROUND: Precision medicine is heralded as offering more effective treatments to smaller targeted patient populations. In breast cancer, adjuvant chemotherapy is standard for patients considered as high-risk after surgery. Molecular tests may identify patients who can safely avoid chemotherapy. OBJECTIVES: To use economic analysis before a large-scale clinical trial of molecular testing to confirm the value of the trial and help prioritize between candidate tests as randomized comparators...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29236174/oncotype-dx%C3%A2-in-breast-cancer-patients-clinical-experience-outcome-and-follow-up-a-case-control-study
#7
Michelle G Rath, Lorenz Uhlmann, Marita Fiedler, Joerg Heil, Michael Golatta, Christine Dinkic, Andre Hennigs, Sarah Schott, Veronika Ernst, Thorsten Koch, Christof Sohn, Cosima Brucker, Joachim Rom
PURPOSE: Breast cancer is the leading cause of death from cancer in women and the most common cancer in the world [1]. To date, many patients with estrogen-receptor-positive (ER+) breast cancer are overtreated with chemotherapy when the rationale for adjuvant chemotherapy is based on clinicopathologic parameters. Different studies were able to demonstrate that a 21-gene expression assay (Oncotype DX® Genomic Health, Redwood City, CA) can predict the benefit from adjuvant chemotherapy in ER+ breast cancers [2, 3] and provide additional prognostic information independent of clinicopathological features [4]...
December 13, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29230662/relationship-of-histologic-grade-and-histologic-subtype-with-oncotype-dx-recurrence-score-retrospective-review-of-863-breast-cancer-oncotype-dx-results
#8
Kamaljeet Singh, Xin He, Elizabeth T Kalife, Shahrzad Ehdaivand, Yihong Wang, C James Sung
PURPOSE: Oncotype Dx (ODx) is a multigene assay that is prognostic and predictive in estrogen receptor (ER) positive early breast cancer. ODx recurrence score (RS) is reported to be histologic grade dependent. Relationship of RS with breast cancer histologic subtypes is unknown. This study was designed to assess the relationship of histologic subtype with RS. Histologic grade dependence of RS was also investigated. METHODS: Results of consecutive ODx tests (1/2007-7/2016) from two institutions were reviewed...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29228411/management-of-breast-cancer-in-adjuvant-chemotherapy-settings-in-the-kanagawa-breast-oncology-group
#9
Mayako Terao, Naoki Niikura, Yasuhiro Suzuki, Norihiko Sengoku, Hitoshi Arioka, Takashi Ishikawa, Koichiro Tsugawa, Yutaka Tokuda
OBJECTIVE: Many different options for adjuvant chemotherapy are recommended in guidelines for the treatment of breast cancer. Therapeutic strategies vary among physicians. The major goals for this project were to gain a better understanding of how biomarkers are integrated into practice and how physicians select adjuvant chemotherapy. METHODS: We assembled a questionnaire with 23 example scenarios of breast cancer cases, including 6 items relevant to postoperative adjuvant therapy...
December 20, 2017: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/29193984/population-based-study-to-determine-the-health-system-costs-of-using-the-21-gene-assay
#10
Nicole Mittmann, Craig C Earle, Stephanie Y Cheng, Jim A Julian, Farah Rahman, Soo Jin Seung, Mark N Levine
Purpose The 21-gene assay Oncotype Dx (Genomic Health, Redwood City, CA) test is used to aid the decision about chemotherapy in patients with hormone receptor-positive breast cancer who received endocrine therapy. Economic studies to support test adoption used decision-analytic models with assumptions and data derived from disparate sources. The objective was to evaluate whether the 21-gene assay test resulted in an overall cost expense or saving to the health system. Patients and Methods One thousand participants enrolled in a field evaluation study, were linked to population-level health system administrative databases, and were observed for 20 months...
December 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29181717/racial-disparities-in-omission-of-oncotype-dx-but-no-racial-disparities-in-chemotherapy-receipt-following-completed-oncotype-dx-test-results
#11
David J Press, Abiola Ibraheem, M Eileen Dolan, Kathleen H Goss, Suzanne Conzen, Dezheng Huo
PURPOSE: To examine racial/ethnic disparities in Oncotype DX (ODX) testing among patients with node-negative, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers and possible racial/ethnic disparities in chemotherapy receipt following ODX testing within Recurrence Score (RS) category (Not Done, Low, Intermediate, High), as well as chemotherapy receipt time trends within RS categories. METHODS: A retrospective cohort list of 125,288 women who were potentially indicated for ODX testing from 2010 to 2014 was obtained using the National Cancer Database...
November 27, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29178616/diffusion-weighted-mri-characteristics-associated-with-prognostic-pathological-factors-and-recurrence-risk-in-invasive-er-her2-breast-cancers
#12
Nita Amornsiripanitch, Vicky T Nguyen, Habib Rahbar, Daniel S Hippe, Vijayakrishna K Gadi, Mara H Rendi, Savannah C Partridge
BACKGROUND: Hormone receptor-positive breast cancer is the most common subtype; better tools to identify which patients in this group would derive clear benefit from chemotherapy are needed. PURPOSE: To evaluate the prognostic potential of diffusion-weighted MRI (DWI) by investigating associations with pathologic biomarkers and a genomic assay for 10-year recurrence risk. STUDY TYPE: Retrospective. SUBJECTS: In all, 107 consecutive patients (from 2/2010 to 1/2013) with estrogen receptor (ER)-positive/HER2neu-negative invasive breast cancer who had the 21-gene recurrence score (RS) test (Oncotype DX, Genomic Health)...
November 27, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29174199/erratum-to-impact-of-oncotype-dx-breast-recurrence-score-testing-on-adjuvant-chemotherapy-use-in-early-breast-cancer-real-world-experience-in-greater-manchester-uk-eur-j-surg-oncol-43-5-2017-931-937
#13
https://www.readbyqxmd.com/read/29147432/the-era-of-multigene-panels-comes-the-clinical-utility-of-oncotype-dx-and-mammaprint
#14
REVIEW
Ling Xin, Yin-Hua Liu, Tracey A Martin, Wen G Jiang
The AJCC Cancer Staging Manual, eighth edition published in late 2016, will become the new global guideline for cancer diagnosis and treatment from January 1, 2018. The new edition for the tumor staging system has numerous updates, including building up the prognostic stage group of tumors for the first time and adding a large number of non-anatomical factors into the prognostic evaluation. Oncotype DX and MammaPrint are two of the genomic predictors that will be part of routine clinical practice in the future...
April 2017: World Journal of Oncology
https://www.readbyqxmd.com/read/29141559/new-histopathological-genetic-features-to-improve-active-surveillance-selection-for-low-risk-prostate-cancer
#15
Lih-Ming Wong, Kevin Chu, Niall Corcoran, Sam Norden
BACKGROUND: A recent surge in biomarkers to aid management of men with prostate cancer has occurred. Their applications are varied and not all tests are applicable to the active surveillance setting. OBJECTIVE: To review primary evidence on genetic and immunohistochemical biomarkers, and their role on patient selection and risk stratification for men on active surveillance for prostate cancer. EVIDENCE ACQUISITION: A PubMed electronic search using the terms (biomarker or genetic or histopathological) AND ("prostate cancer" AND "active surveillance") was performed from inception to April 2015...
November 13, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29138761/a-metastasis-biomarker-metasite-breast%C3%A2-score-is-associated-with-distant-recurrence-in-hormone-receptor-positive-her2-negative-early-stage-breast-cancer
#16
Joseph A Sparano, Robert Gray, Maja H Oktay, David Entenberg, Thomas Rohan, Xiaonan Xue, Michael Donovan, Michael Peterson, Anthony Shuber, Douglas A Hamilton, Timothy D'Alfonso, Lori J Goldstein, Frank Gertler, Nancy E Davidson, John Condeelis, Joan Jones
Metastasis is the primary cause of death in early-stage breast cancer. We evaluated the association between a metastasis biomarker, which we call "Tumor Microenviroment of Metastasis" (TMEM), and risk of recurrence. TMEM are microanatomic structures where invasive tumor cells are in direct contact with endothelial cells and macrophages, and which serve as intravasation sites for tumor cells into the circulation. We evaluated primary tumors from 600 patients with Stage I-III breast cancer treated with adjuvant chemotherapy in trial E2197 (NCT00003519), plus endocrine therapy for hormone receptor (HR)+ disease...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29135103/impact-of-oncotype-dx-on-chemotherapy-assignment-a-retrospective-single-center-study-on-female-breast-cancer-patients
#17
Dimitris Panousis, Panagiota Ntasiou, Dimitris Grosomanidis, Konstantinos Chatzopoulos, Georgia Paraskevakou, Panagiota Kontogianni, Efstratia Charitidou, Grigoris Xepapadakis
PURPOSE: This study was designed to determine the Recurrence Score (RS) distribution and its associated risk assessments based on traditional clinicopathologic characteristics in a single-center breast cancer (BC) deriving cohort in Greece, and to evaluate the impact of the RS results on adjuvant treatment decisions applied in this cohort. METHODS: This was a retrospective, single-center study regarding Greek female patients with early-stage breast cancer (ESBC)...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29129398/genomic-markers-in-prostate-cancer-decision-making
#18
REVIEW
Vito Cucchiara, Matthew R Cooperberg, Marc Dall'Era, Daniel W Lin, Francesco Montorsi, Jack A Schalken, Christopher P Evans
CONTEXT: Although the widespread use of prostate-specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA remains one of the most controversial biomarkers due to its limited specificity. As part of emerging efforts to improve both detection and management decision making, a number of new genomic tools have recently been developed. OBJECTIVE: This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive tumors, and facilitate the selection of therapies in patients with advanced disease...
November 9, 2017: European Urology
https://www.readbyqxmd.com/read/29128896/discordance-between-oncotype-dx-recurrence-score-and-rspc-for-predicting-residual-risk-of-recurrence-in-er-positive-breast-cancer
#19
Andrew Dodson, David Okonji, Laura Assersohn, Anne Rigg, Amna Sheri, Nick Turner, Ian Smith, Marina Parton, Mitch Dowsett
PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) related to distant disease recurrence (DR) risk (RS%). In node-negative patients, RS can be integrated with clinicopathological parameters to derive RS-pathology-clinical (RSPC) that improves prognostic accuracy. METHODS: Data were collected on patients having clinically indicated tests with an intermediate clinical risk of distant recurrence, and for whom the decision to prescribe chemotherapy remained unclear...
November 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29128582/budget-impact-analysis-of-gene-expression-tests-to-aid-therapy-decisions-for-breast-cancer-patients-in-germany
#20
M P Lux, N Nabieva, T Hildebrandt, H Rebscher, S Kümmel, J-U Blohmer, M G Schrauder
OBJECTIVES: Many women with early-stage, hormone receptor-positive breast cancer may not benefit from adjuvant chemotherapy. Gene expression tests can reduce chemotherapy over- and undertreatment by providing prognostic information on the likelihood of recurrence and, with Oncotype DX, predictive information on chemotherapy benefit. These tests are currently not reimbursed by German healthcare payers. An analysis was conducted to evaluate the budget impact of gene expression tests in Germany...
November 9, 2017: Breast: Official Journal of the European Society of Mastology
keyword
keyword
84415
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"